x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The IMID Forum

The Immune-Mediated Inflammatory Disease Forum

Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.

education

All Episodes

00:18:42

Discussing AxSpA Podcast: Efficacy and Safety of...

The IMID Forum ·

2024/12/19

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenfon Baraliakos to discuss a recent study on the efficacy and safety of upadacitinib in patient with ankylosing spondylitis.

en

00:30:53

PsA Podcast: DISCOVER-2 and BE OPTIMAL/BE COMPLETE...

The IMID Forum ·

2024/11/28

Join Professors Peter Nash and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a post hoc analysis examining the rapid and sustained efficacy of bimekizumab in PsA patients across different subgroups, focusing on improvements in pain, fatigue, and physical function over 16 weeks. The conversation also covered a long-term analysis of guselkumab assessing the durability of clinical improvements in joint and skin symptoms in PsA patients over

en

00:50:04

ACR 2024 Review Podcast

The IMID Forum ·

2024/11/28

ACR 2024 Review Podcast by The Immune-Mediated Inflammatory Disease Forum

en

00:19:16

Discussing RA: Insights into Filgotinib and...

The IMID Forum ·

2024/11/14

Join Professor Iain McInnes and Professor Johannes Bijlsma for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.

en

00:26:39

Webinar Highlights Podcast: CAR T-cell Therapy: An...

The IMID Forum ·

2024/11/13

Webinar Highlights Podcast: Join Professor Iain McInnes and Professor Georg Schett as they discuss the recent webinar hosted on the IMID Forum: “CAR T-cell Therapy: An Emerging Therapy in Autoimmune Diseases”. Listen to them discuss key highlights from the webinar including the development of CAR T-cell therapy, the application of CAR T to autoimmune diseases, and the potential risks and reservations associated with this therapeutic approach.

en

00:02:55

ACR 2024 Highlights: Day 1

The IMID Forum ·

2024/11/11

ACR 2024 Highlights: Day 1 by The Immune-Mediated Inflammatory Disease Forum

en

00:03:36

ACR 2024 Highlights: Day 2

The IMID Forum ·

2024/11/11

ACR 2024 Highlights: Day 2 by The Immune-Mediated Inflammatory Disease Forum

en

00:19:51

ACR 2024: Preview Podcast

The IMID Forum ·

2024/11/11

ACR 2024: Preview Podcast by The Immune-Mediated Inflammatory Disease Forum

en

00:04:21

ACR 2024 Highlights: Day 3

The IMID Forum ·

2024/11/11

ACR 2024 Highlights: Day 3 by The Immune-Mediated Inflammatory Disease Forum

en

00:23:30

AxSpA Podcast: Efficacy and Safety of IV secukinumab

The IMID Forum ·

2024/10/31

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, and Atul Deodhar to discuss a recent study on the efficacy and safety of IV secukinumab in patient with active axSpA.

en

00:22:03

Discussing RA: Navigating JAKis, TNFis, and the quest...

The IMID Forum ·

2024/10/31

Join Professor Iain McInnes and Professor Leonard Calabrese for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the efficacy and safety of JAK inhibitors and TNF inhibitors for rheumatoid arthritis, while also uncovering the best treatment strategies for difficult-to-treat RA.

en

00:33:27

Author Interview: Derin Karacabeyli, 2024

The IMID Forum ·

2024/10/10

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Derin Karacabeyli of Arthritis Research Canada, a rheumatologist and resident in the University of British Columbia Clinician Investigator Program, as they discuss his recent paper ‘Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study’, published in PLoS One on 08th August

en

00:32:56

Webinar Highlights Podcast 2: Evolving Therapeutic...

The IMID Forum ·

2024/10/07

Webinar Highlights Podcast: Join Professor Christopher Ritchlin, and Professor Philip Mease as they discuss the recent webinar hosted on the IMID Forum ‘Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar - Part 2’. Watch them discuss key highlights from the webinar including the burden of PsA and PsO, the similarities and differences in pathology in skin and joints across psoriatic arthritis, and a special focus on IL-23, and its clinical data and impact

en

00:21:04

PsA Podcast: Bimekizumab: Efficacy, safety, and...

The IMID Forum ·

2024/09/26

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a matching-adjusted indirect comparison (MAIC) to assess the comparative efficacy of bimekizumab and risankizumab in patients with psoriatic arthritis over 52 weeks, and a post hoc analysis investigating the efficacy and safety of bimekizumab in PsA patients with or without concomitant methotrexate over 52 weeks.

en

00:19:24

Discussing RA: Long-term safety and efficacy of...

The IMID Forum ·

2024/09/19

Join Professor Iain McInnes and Professors Hideto Kameda and Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the long-term efficacy and safety of upadacitinib in the SELECT trials.

en

00:24:11

Discussing AxSpA: Incidence of uveitis following...

The IMID Forum ·

2024/08/29

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenofon Baraliakos to discuss a recent study on the incidence of uveitis in patients with axSpA that were treated with bimekizumab.

en

00:44:09

Author Interview: Professor Laura Andreoli, 2024

The IMID Forum ·

2024/08/22

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Laura Andreoli, a Professor of Rheumatology at the University of Brescia, as they discuss her recent paper ‘The outcomes of children born to mothers with autoimmune rheumatic diseases’, published in The Lancet. Rheumatology on 11th June 2024.

en

00:16:05

Discussing RA: Neutrophil-to-lymphocyte ratio and...

The IMID Forum ·

2024/08/15

Join Professor Iain McInnes and Professors Hideto Kameda and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss a paper that investigated whether the baseline neutrophil-to-lymphocyte ratio had an effect on the treatment response to filgotinib.

en

00:21:07

Author Interview: Dr Adam Goldman, 2024

The IMID Forum ·

2024/08/08

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Adam Goldman, an epidemiology researcher at The Chaim Sheba Medical Center in Tel-Hashomer, and an epidemiology researcher and lecturer at Tel-Aviv University, as they discuss his recent paper ‘Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports’, published in Seminars in Arthritis and Rheumatism on 17th May 2024.

en

00:26:44

Author Interview: Professor Daniel Blockmans, 2024

The IMID Forum ·

2024/07/25

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Daniel Blockmans, from the Department of Internal Medicine at the University Hospitals Leuven, as they discuss his recent paper ‘Efficacy and safety of upadacitinib in patients with giant cell arteritis (SELECT-GCA): A double-blind, randomized controlled Phase 3 trial’, published in Annals of the Rheumatic Diseases on June 2024.

en

396 results

Similar Podcasts

Science Talk

Albert Einstein College of Medicine

五分钟心理学

柠檬心理

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Veterinary Clinical Podcasts

The Royal Veterinary College